These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 23482784)

  • 1. Phase II study of carboplatin and weekly irinotecan combination chemotherapy in recurrent ovarian cancer: a Kansai clinical oncology group study (KCOG0330).
    Tsubamoto H; Kawaguchi R; Ito K; Shiozaki T; Takeuchi S; Itani Y; Arakawa A; Tabata T; Toyoda S
    Anticancer Res; 2013 Mar; 33(3):1073-9. PubMed ID: 23482784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
    del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
    Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: a phase II trial.
    Shawky H; Tawfik H; Hewidy M
    J Egypt Natl Canc Inst; 2014 Sep; 26(3):139-45. PubMed ID: 25150129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
    Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
    BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
    Briasoulis E; Golfinopoulos V; Karina M; Papakostas P; Pavlidis N; Fountzilas G
    Anticancer Drugs; 2010 Sep; 21(8):785-9. PubMed ID: 20647930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T
    Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
    J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
    van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
    Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
    Selle F; Sevin E; Ray-Coquard I; Mari V; Berton-Rigaud D; Favier L; Fabbro M; Lesoin A; Lortholary A; Pujade-Lauraine E
    Ann Oncol; 2014 Nov; 25(11):2191-2196. PubMed ID: 25210017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
    Strauss HG; Henze A; Teichmann A; Karbe I; Baumgart A; Thomssen C; Koelbl H
    Gynecol Oncol; 2007 Mar; 104(3):612-6. PubMed ID: 17069876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
    Sugiyama T; Okamoto A; Enomoto T; Hamano T; Aotani E; Terao Y; Suzuki N; Mikami M; Yaegashi N; Kato K; Yoshikawa H; Yokoyama Y; Tanabe H; Nishino K; Nomura H; Kim JW; Kim BG; Pignata S; Alexandre J; Green J; Isonishi S; Terauchi F; Fujiwara K; Aoki D
    J Clin Oncol; 2016 Aug; 34(24):2881-7. PubMed ID: 27400948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
    Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD
    Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
    Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
    Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
    Kang H; Kim TJ; Lee YY; Choi CH; Lee JW; Bae DS; Kim BG
    Gynecol Oncol; 2009 Aug; 114(2):210-4. PubMed ID: 19446320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The "Leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study.
    Cadron I; Abdulkadir L; Despierre E; Berteloot P; Neven P; Leunen K; Amant F; Vergote I
    Gynecol Oncol; 2013 Jan; 128(1):34-37. PubMed ID: 23063762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.
    Sorbe B; Graflund M; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
    Int J Gynecol Cancer; 2012 Jan; 22(1):47-53. PubMed ID: 22193643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.
    Escobar PF; Markman M; Rose P; Zanotti K; Webster K; Belinson J
    Gynecol Oncol; 2004 Jan; 92(1):192-6. PubMed ID: 14751157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
    Alvarez Secord A; Berchuck A; Higgins RV; Nycum LR; Kohler MF; Puls LE; Holloway RW; Lewandowski GS; Valea FA; Havrilesky LJ
    Cancer; 2012 Jul; 118(13):3283-93. PubMed ID: 22072307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.
    Kimball KJ; Numnum TM; Kirby TO; Zamboni WC; Estes JM; Barnes MN; Matei DE; Koch KM; Alvarez RD
    Gynecol Oncol; 2008 Oct; 111(1):95-101. PubMed ID: 18692224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.